<p>Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia</p>-Reference-Cited by-同舟云学术

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia

Published:2020-06 Issue: Volume:Volume 12 Page:333-343
ISSN:1178-6981
Container-title:ClinicoEconomics and Outcomes Research
language:en
Short-container-title:CEOR

Author:

Shafie Asrul Akmal^ORCID,Ng Chin Hui

Publisher

Informa UK Limited

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference51 articles.

1. Ruxyn T More than a million adults in Malaysia are not even aware they have diabetes. SAYS. 2018.

2. Diabetes Care in Malaysia: Problems, New Models, and Solutions

3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. doi:10.1016/S0140-6736(98)07019-6

4. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Evaluating the Impact of Intensifying Treatment from Human to Analogue Insulin on Glycaemic Control and Insulin Expenditure in Patients with Type 2 Diabetes: A Retrospective Cohort Study;Malaysian Journal of Medical Sciences;2024-04-23

3. Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis;Medicine;2023-10-27

4. Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials;Cureus;2023-08-29

5. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China;Frontiers in Pharmacology;2023-08-09